The potential of EGCG to modulate gene expression in the Ts65Dn mouse model for DS has limited evidence, with one study administering 200 mg/kg EGCG on embryonic days 7 and 8 twice daily showing decreases in Protein patched homolog 1 (Ptch) and Ets2 RNA expression and significant increases in Rcan1 and Shh RNA expression in the first pharyngeal arch of Ts65Dn mice at embryonic day (E) 9.5 (McElyea et al., 2016). The gene discussed is PTCH1; the disease is Dravet syndrome.